{
  "id": "0145f44ad6294c71",
  "title": "Takeda R & D Exec Explains How $1 . 2B Deal Could Become One of the Biggest Bargains in Drug History",
  "description": "20260116T050000Z",
  "content": "",
  "source": "medcitynews.com",
  "source_url": "https://medcitynews.com/2026/01/takeda-andy-plump-innovent-bispecific-antibody-cancer-oncology-adc-tak/",
  "published_at": "20260116T050000Z",
  "fetched_at": "2026-01-17T00:22:29.333379+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "drug",
    "ai"
  ],
  "location": "United States",
  "raw_data": {
    "url": "https://medcitynews.com/2026/01/takeda-andy-plump-innovent-bispecific-antibody-cancer-oncology-adc-tak/",
    "url_mobile": "",
    "title": "Takeda R & D Exec Explains How $1 . 2B Deal Could Become One of the Biggest Bargains in Drug History",
    "seendate": "20260116T050000Z",
    "socialimage": "https://medcitynews.com/wp-content/uploads/sites/7/2026/01/Andy-Plump-headshot_Takeda.jpg",
    "domain": "medcitynews.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}